Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.

被引：0

作者：

Dummer, Reinhard

Queirolo, Paola

Guijarro, Ana Maria Abajo

Hu, Youyou

Wang, Dao

Azevedo, Sergio Jobim

Robert, Caroline

Ascierto, Paolo Antonio

Chiarion-Sileni, Vanna

Pronzato, Paolo

Spagnolo, Francesco

Mujika, Karmele

Liszkay, Gabriella

Merino, Luis De la Cruz

Tawbi, Hussein A.

机构：

[1] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland

[2] IRCCS, Ist Europeo Oncol, Milan, Italy

[3] F Hoffmann Roche Ltd, Basel, Switzerland

[4] Hosp Clinicas Porto Alegre, Unidade Pesquisa Clin Oncol, Porto Alegre, RS, Brazil

[5] Gustave Roussy, Villejuif Paris, France

[6] Univ Paris Saclay, Villejuif Paris, France

[7] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[8] IRCCS, Ist Oncol Veneto IOV, Padua, Italy

[9] IRCCS Osped, Policlin San Martino, Genoa, Italy

[10] Onkol Hosp, Donostia San Sebastian, Spain

[11] Orszagos Onkol Int, Budapest, Hungary

[12] Hosp Univ Virgen Macarena, Seville, Spain

[13] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9515

引用

页数：1

共 38 条

[21] Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) plus vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma. [J].

Robert, Caroline ;

Lewis, Karl D. ;

Ascierto, Paolo Antonio ;

Munhoz, Rodrigo Ramella ;

Liszkay, Gabriella ;

de la Cruz-Merino, Luis ;

Olah, Judit ;

Queirolo, Paola ;

Mackiewicz, Jacek ;

Caro, Ivor ;

Shah, Kalpit ;

Forbes, Harper ;

Li, Haocheng ;

Hertig, Christian ;

Yan, Yibing ;

Mckenna, Edward Francis ;

Gutzmer, Ralf ;

McArthur, Grant A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[22] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (vol 395, pg 1835, 2020) [J].

Gutzmer, R. ;

Stroyakovskiy, D. ;

Gogas, H. ;

Robert, Caroline ;

Lewis, Karl ;

Protsenko, Svetlana ;

Pereira, Rodrigo P. ;

Eigentler, Thomas ;

Rutkowski, Piotr ;

Demidov, Lev ;

Manikhas, Georgy Moiseevich ;

Yan, Yibing ;

Huang, Kuan-Chieh ;

Uyei, Anne ;

McNally, Virginia ;

McArthur, Grant A. ;

Ascierto, Paolo A. .

LANCET, 2020, 396 (10249) :466-466

[23] Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial [J].

Arance, A. M. ;

Gogas, H. ;

Dreno, B. ;

Flaherty, K. T. ;

Demidov, L. ;

Stroyakovskiy, D. ;

Eroglu, Z. ;

Ferrucci, P. F. ;

Pigozzo, J. ;

Rutkowski, P. ;

Mackiewicz, J. ;

Rooney, I. ;

Voulgari, A. ;

Troutman, S. ;

Pitcher, B. ;

Yan, Y. ;

Larkin, J. M. G. .

ANNALS OF ONCOLOGY, 2019, 30 :906-906

[24] coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) [J].

Paolo A Ascierto ;

Grant A. McArthur ;

Brigitte Dréno ;

James Larkin ;

Gabriella Liszkay ;

Michele Maio ;

Mario Mandala ;

Lev Demidov ;

Daniil Stroyakovskiy ;

Luc Thomas ;

Luis de la Cruz-Merino ;

Victoria Atkinson ;

Caroline Dutriaux ;

Claus Garbe ;

Ilsung Chang ;

Stephen P. Hack ;

Antoni Ribas .

Journal of Translational Medicine, 13 (Suppl 1)

[25] TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs. placebo plus C combined with v in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54) [J].

Ascierto, P. ;

Lewis, K. ;

McArthur, G. ;

Rooney, I. ;

McNally, V. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 :46-47

[26] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study [J].

Dummer, Reinhard ;

Welti, Michele ;

Ramelyte, Egle .

JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)

[27] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study [J].

Reinhard Dummer ;

Michèle Welti ;

Egle Ramelyte .

Journal of Translational Medicine, 21

[28] Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets) [J].

Seetharam, Mahesh ;

Dronca, Roxana ;

Dudek, Arkadiusz Z. ;

Nelson, Garth ;

Block, Matthew ;

Starling, Skylar ;

Baskin, Amber ;

Bradshaw, Renee ;

Nelson, Courtney ;

Andrews, Kylee ;

Birgin, Alisha ;

Watson, Cristina ;

Yan, Yiyi ;

Mahadevan, Daruka ;

Markovic, Svetomir ;

Myers, Tom ;

Paradiso, Linda ;

Babiker, Hani .

CANCER RESEARCH, 2024, 84 (07)

[29] Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis [J].

Blank, Christian U. ;

Larkin, James ;

Arance, Ana M. ;

Hauschild, Axel ;

Queirolo, Paola ;

Del Vecchio, Michele ;

Ascierto, Paolo A. ;

Krajsova, Ivana ;

Schachter, Jacob ;

Neyns, Bart ;

Garbe, Claus ;

Sileni, Vanna Chiarion ;

Mandala, Mario ;

Gogas, Helen ;

Espinosa, Enrique ;

Hospers, Geke A. P. ;

Miller, Wilson H., Jr. ;

Robson, Susan ;

Makrutzki, Martina ;

Antic, Vladan ;

Brown, Michael P. .

EUROPEAN JOURNAL OF CANCER, 2017, 79 :176-184

[30] BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). [J].

Kirkwood, John M. ;

Long, Georgina V. ;

Trefzer, Uwe ;

Davies, Michael A. ;

Ascierto, Paolo Antonio ;

Chapman, Paul B. ;

Puzanov, Igor ;

Hauschild, Axel ;

Robert, Caroline ;

Kefford, Richard ;

Goodman, Vicki L. ;

Switzky, Julie C. ;

Swann, R. Suzanne ;

Martin, Anne-Marie ;

Guckert, Mary E. ;

Streit, Michael R. W. ;

Schadendorf, Dirk .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 →